Advertisement
MBX vs SVRA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MBX is a StrongBuy and SVRA is a Hold.
MBX's RSI Oscillator ascending out of oversold territory
The RSI Oscillator for MBX moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 8 similar instances when the indicator left oversold territory. In 8 of the 8 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on MBX as a result. In 24 of 31 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for MBX just turned positive on October 26, 2026. Looking at past instances where MBX's MACD turned positive, the stock continued to rise in 13 of 15 cases over the following month. The odds of a continued upward trend are 87%.
MBX moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +9.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where MBX advanced for three days, in 122 of 133 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
MBX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 20 of 20 cases where MBX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for MBX entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 10 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.039) is normal, around the industry mean (3.498). P/E Ratio (-21.667) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. MBX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
SVRA in upward trend: price expected to rise as it breaks its lower Bollinger Band on October 23, 2026
SVRA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 35 of 40 cases where SVRA's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SVRA's RSI Indicator exited the oversold zone, 16 of 19 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on SVRA as a result. In 73 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for SVRA just turned positive on October 27, 2026. Looking at past instances where SVRA's MACD turned positive, the stock continued to rise in 29 of 42 cases over the following month. The odds of a continued upward trend are 69%.
Following a +15.30% 3-day Advance, the price is estimated to grow further. Considering data from situations where SVRA advanced for three days, in 191 of 242 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
SVRA moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SVRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for SVRA entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 44 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 51 (best 1 - 100 worst), indicating steady price growth. SVRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.908) is normal, around the industry mean (3.498). P/E Ratio (-8.328) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
SVRA | ||
|---|---|---|
OUTLOOK RATING 1..100 | 62 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | |
PROFIT vs RISK RATING 1..100 | 44 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 51 | |
P/E GROWTH RATING 1..100 | 30 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| MBX | SVRA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 79% |
| Momentum ODDS (%) | 2 days ago 77% | 2 days ago 74% |
| MACD ODDS (%) | 2 days ago 87% | 2 days ago 69% |
| TrendWeek ODDS (%) | 2 days ago 89% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 78% |
| Advances ODDS (%) | 2 days ago 90% | 3 days ago 79% |
| Declines ODDS (%) | 7 days ago 86% | 7 days ago 83% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 83% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MBX’s FA Score shows that 1 FA rating(s) are green while SVRA’s FA Score has 1 green FA rating(s).
- MBX’s FA Score: 1 green, 4 red.
- SVRA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MBX’s TA Score shows that 6 TA indicator(s) are bullish while SVRA’s TA Score has 5 bullish TA indicator(s).
- MBX’s TA Score: 6 bullish, 3 bearish.
- SVRA’s TA Score: 5 bullish, 4 bearish.
Price Growth
MBX (@Biotechnology) experienced а +2.42% price change this week, while SVRA (@Biotechnology) price change was +3.58% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
SVRA is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
MBX and
Correlation & Price change
A.I.dvisor indicates that over the last year, MBX has been loosely correlated with SVRA. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if MBX jumps, then SVRA could also see price increases.
| Ticker / NAME | Correlation To MBX | 1D Price Change % | ||
|---|---|---|---|---|
| MBX | 100% | +4.20% | ||
| SVRA - MBX | 42% Loosely correlated | -2.57% | ||
| NAMS - MBX | 40% Loosely correlated | +0.95% | ||
| SYRE - MBX | 40% Loosely correlated | -4.15% | ||
| IMVT - MBX | 40% Loosely correlated | +1.59% | ||
| KURA - MBX | 39% Loosely correlated | N/A | ||
More | ||||
SVRA and
Correlation & Price change
A.I.dvisor indicates that over the last year, SVRA has been loosely correlated with FDMT. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SVRA jumps, then FDMT could also see price increases.
| Ticker / NAME | Correlation To SVRA | 1D Price Change % | ||
|---|---|---|---|---|
| SVRA | 100% | -2.57% | ||
| FDMT - SVRA | 51% Loosely correlated | -0.16% | ||
| MGTX - SVRA | 47% Loosely correlated | +1.37% | ||
| ANNX - SVRA | 46% Loosely correlated | -0.47% | ||
| KURA - SVRA | 45% Loosely correlated | N/A | ||
| CLDX - SVRA | 44% Loosely correlated | -1.89% | ||
More | ||||